Skip to main content

Advertisement

Log in

Prognostic Benefit of Additional Treatment After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Although additional treatment is considered for patients with esophageal squamous cell carcinoma (ESCC) invading into the muscularis mucosa (pT1a-MM) or submucosa (pT1b-SM) after endoscopic submucosal dissection (ESD), the actual benefits of this method remain to be elucidated.

Aims

We aimed to evaluate the prognostic benefits of additional treatment in such patients.

Methods

Between 2006 and 2017, we enrolled patients with pT1a-MM/pT1b-SM ESCC after ESD at 21 institutions in Japan. Overall survival (OS) and disease-specific survival (DSS) were compared between the additional treatment and follow-up groups after propensity score matching, to reduce the bias of baseline characteristics. A subgroup analysis was performed according to the pathological findings: category A, pT1a-MM but negative for lymphovascular invasion (LVI) and vertical margin (VM); category B, tumor invasion into the submucosa ≤ 200 μm but negative for LVI and VM; category C, others.

Results

Of 593 patients with pT1a-MM/pT1b-SM ESCC after ESD, 101 matched pairs were extracted after propensity score matching. The OSs were similar between the additional treatment and follow-up groups (80.6% vs. 78.6% in 5 years; P = 0.972). In a subgroup analysis, the OS in the additional treatment group was significantly lower than that in the follow-up group (65.7% vs. 95.2% in 5 years; P = 0.037) in category A, whereas OS did not significantly differ in category C (76.8% vs. 69.5% in 5 years; P = 0.360).

Conclusions

Additional treatment after ESD in patients with pT1a-MM/pT1b-SM ESCC was not associated with an improved prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

LNM:

Lymph node metastasis

ESCC:

Esophageal squamous cell carcinoma

pT1a-MM:

Tumor invasion into the muscularis mucosa

pT1b-SM:

Tumor invasion into the submucosa

CRT:

Chemoradiotherapy

OS:

Overall survival

ESD:

Endoscopic submucosal dissection

LVI:

Lymphovascular invasion

VM:

Vertical margin

DSS:

Disease-specific survival

IQR:

Interquartile range

PS:

Propensity score

CCI:

Charlson comorbidity index

PNI:

Prognostic nutrition index

ASD:

Absolute standardized difference

AUROC:

Area under the receiver operating characteristic curve

HR:

Hazard ratio

CI:

Confidence interval

pT1b-SM1:

Tumor invasion into the submucosa ≤ 200 μm

pT1b-SM2:

Tumor invasion into the submucosa > 200 μm

References

  1. Ishihara R, Arima M, Iizuka T et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 2020;32:452–493.

    Article  PubMed  Google Scholar 

  2. Ono H, Yao K, Fujishiro M et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (Second edition). Dig Endosc 2021;33:4–20.

    Article  PubMed  Google Scholar 

  3. Hatta W, Gotoda T, Koike T, Masamune A. History and future perspectives in Japanese guidelines for endoscopic resection of early gastric cancer. Dig Endosc 2020;32:180–190.

    Article  PubMed  Google Scholar 

  4. Tanaka S, Kashida H, Saito Y et al. Japan Gastroenterological Endoscopy Society guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection. Dig Endosc 2020;32:219–239.

    Article  PubMed  Google Scholar 

  5. Kitagawa Y, Uno T, Oyama T et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus 2019;16:1–24.

    Article  PubMed  Google Scholar 

  6. Kitagawa Y, Uno T, Oyama T et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus 2019;16:25–43.

    Article  PubMed  Google Scholar 

  7. Hatta W, Gotoda T, Koike T, Masamune A. Management following endoscopic resection in elderly patients with early-stage upper gastrointestinal neoplasia. Dig Endosc 2020;32:861–873.

    Article  PubMed  Google Scholar 

  8. Iwai N, Dohi O, Yamada S et al. Prognostic risk factors associated with esophageal squamous cell carcinoma patients undergoing endoscopic submucosal dissection: a multi-center cohort study. Surg Endosc 2022;36:2279–2289.

    Article  PubMed  Google Scholar 

  9. Ogata Y, Hatta W, Koike T et al. Predictors of early and late mortality after endoscopic resection for esophageal squamous cell carcinoma. Tohoku J Exp Med 2021;253:29–39.

    Article  CAS  PubMed  Google Scholar 

  10. Tsujii Y, Nishida T, Nishiyama O et al. Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms: a multicenter retrospective cohort study. Endoscopy 2015;47:775–783.

    Article  PubMed  Google Scholar 

  11. Takahashi K, Hashimoto S, Mizuno KI et al. Management decision based on lymphovascular involvement leads to favorable outcomes after endoscopic treatment of esophageal squamous cell carcinoma. Endoscopy 2018;50:662–670.

    Article  PubMed  Google Scholar 

  12. Naito S, Yoshio T, Ishiyama A et al. Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment. Dig Endosc 2022;34:793–804.

    Article  PubMed  Google Scholar 

  13. Yoshii T, Ohkawa S, Tamai S, Kameda Y. Clinical outcome of endoscopic mucosal resection for esophageal squamous cell cancer invading muscularis mucosa and submucosal layer. Dis Esophagus 2013;26:496–502.

    Article  CAS  PubMed  Google Scholar 

  14. Ikeda A, Hoshi N, Yoshizaki T et al. Endoscopic submucosal dissection (ESD) with additional therapy for superficial esophageal cancer with submucosal invasion. Intern Med 2015;54:2803–2813.

    Article  PubMed  Google Scholar 

  15. Hisano O, Nonoshita T, Hirata H et al. Additional radiotherapy following endoscopic submucosal dissection for T1a-MM/T1b-SM esophageal squamous cell carcinoma improves locoregional control. Radiat Oncol 2018;13:14.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hatta W, Koike T, Takahashi S et al. Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study. J Gastroenterol 2021;56:620–632.

    Article  PubMed  Google Scholar 

  17. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus 2017;14:1–36.

    Article  Google Scholar 

  18. Katada C, Muto M, Momma K et al. Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae—a multicenter retrospective cohort study. Endoscopy 2007;39:779–783.

    Article  CAS  PubMed  Google Scholar 

  19. Toya Y, Endo M, Nakamura S et al. Long-term outcomes and prognostic factors with non-curative endoscopic submucosal dissection for gastric cancer in elderly patients aged >/= 75 years. Gastric Cancer 2019;22:838–844.

    Article  PubMed  Google Scholar 

  20. Nakajo K, Abe S, Oda I et al. Impact of the Charlson Comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma: a multicenter retrospective study. J Gastroenterol 2019;54:871–880.

    Article  CAS  PubMed  Google Scholar 

  21. Sekiguchi M, Oda I, Suzuki H et al. Clinical outcomes and prognostic factors in gastric cancer patients aged ≥85 years undergoing endoscopic submucosal dissection. Gastrointest Endosc 2017;85:963–972.

    Article  PubMed  Google Scholar 

  22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.

    Article  CAS  PubMed  Google Scholar 

  23. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 1984;85:1001–1005 (in Japanese).

    CAS  PubMed  Google Scholar 

  24. Ogata Y, Hatta W, Ohara Y et al. Predictors of early and late mortality after the treatment for early gastric cancers. Dig Endosc 2022;34:816–825.

    Article  PubMed  Google Scholar 

  25. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083–3107.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Tamotsu Matsuhashi (Akita University Graduate School of Medicine), Yohei Ogata and Hiroko Abe (Tohoku University Graduate School of Medicine), Yoshihiro Harada, Taku Yamagata, and Yoshiki Koike (Sendai City Medical Center), Mika Takasumi, Minami Hashimoto, and Tsunetaka Kato (Fukushima Medical University Hospital), Yu Sasaki, Makoto Yagi, and Yasuhiko Abe (Yamagata University), Yoshinori Horikawa (Southern-Tohoku General Hospital), Kennichi Satoh and Itaru Satoh (Tohoku Medical and Pharmaceutical University School of Medicine), Ryoichi Ishihata (Ohara General Hospital), Fumitake Ishiyama and Hirohiko Shinkai (Iwate Prefectural Isawa Hospital), Motoki Ohyauchi (Osaki Citizen Hospital), Tetsuya Tatsuta, Hidezumi Kikuchi, and Daisuke Chinda (Hirosaki University Hospital), Wataru Iwai, Tetsuya Noguchi, and Takefumi Miyazaki (Miyagi Cancer Center), Nobuyuki Ara (National Hospital Organization Sendai Medical Center), Shuichi Ohara (Tohoku Rosai Hospital), Jun Fushiya (Iwate Prefectural Central Hospital), Hiroaki Takeda, Nakao Shirahata, and Shoichiro Fujishima (Yamagata Prefectural Central Hospital), and Goro Shibukawa (Fukushima Medical University Aizu Medical Center) for the patient enrollment, data collection, and/or intellectual comment.

Funding

There are no grant supports in this study.

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: WH, KI; Methodology: ST, WH, KI; Acquisition of data: ST, WH, KW, TS, TH, YT, IT, YO, KH, DF, KW, SK, HI, TM, TO, YT, YK, TY, TS, KN, NH, AF, DH, TO, JN; Formal analysis and investigation: ST, WH; Statistical review: TN, NN; Writing—original draft preparation: ST, WH; Writing—review and editing: TK, KI; Supervision: TM, SF, AM, KI.

Corresponding author

Correspondence to Waku Hatta.

Ethics declarations

Conflict of interest

Katsunori Iijima received lecture fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd. All other authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takahashi, S., Hatta, W., Watanabe, K. et al. Prognostic Benefit of Additional Treatment After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma. Dig Dis Sci 68, 2050–2060 (2023). https://doi.org/10.1007/s10620-022-07746-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-022-07746-8

Keywords

Navigation